Name | 2-Hydroxy-3''-Nitro-Biphenyl-3-Carboxylic Acid |
Synonyms | Eltrombopag o Eltrombopag Impurity 13 Eltrombopag olamine Intermediate 2 3-(2-hydroxy-3-nitrophenyl)benzoic acid 2'-hydroxy-3'-nitro-3-biphenylcarboxylic acid 2-HYDROXY-3''-NITRO-BIPHENYL-3-CARBOXYLIC ACID 2-Hydroxy-3''-Nitro-Biphenyl-3-Carboxylic Acid 3'-Nitro-2'-hydroxy[1,1']-biphenyl-3-carboxylic Acid 3'-NITRO-2'-HYDROXY[1,1']-BIPHENYL-3-CARBOXYLIC ACID 2'-Hydroxy-3'-nitro-[1,1'-biphenyl]-3-carboxylic acid [1,1'-Biphenyl]-3-carboxylicacid, 2'-hydroxy-3'-nitro- |
CAS | 376591-95-6 |
Molecular Formula | C13H9NO5 |
Molar Mass | 259.21 |
Density | 1.460±0.06 g/cm3(Predicted) |
Boling Point | 452.2±40.0 °C(Predicted) |
Solubility | Tetrahydrofuran; Methanol; |
Appearance | Solid |
Color | Yellow |
pKa | 3.96±0.10(Predicted) |
Storage Condition | Room Temperature |
overview | eltrombopa (eltrombopag, trade name is Promacta), developed by GlaxoSmithKline, UK, was approved by FDA in November 2008 and listed in the United States. it is an oral thrombopoietin drug, a small molecule thrombopoietin receptor agonist, which can interact with thrombopoietin receptors in the transmembrane region of the human body, it produces signal cascade amplification, which induces proliferation and differentiation of bone marrow megakaryocytes. It is mainly used to treat thrombocytopenia in patients with chronic idiopathic thrombocytopenic purpura (ITP) after splenectomy after glucocorticoid drugs, immunoglobulin therapy is ineffective or splenectomy. |
Application | Etrombopa (eltrombopag), chemical name 3'-{(2Z)-2-[1-(3, 4-xylene)-3-Methyl -5-oxo-1, 5-Dihydro-4H-pyrazol-4-subunit] hydrazinyl}-2 '-hydroxy-3-biphenyl formic acid. From the structure of the compound, the synthesis of the compound contains two important intermediates: 2-hydroxy-3'-nitro-biphenyl-3-carboxylic acid (BPCA) and 1-(3, 4-Dimethylphenyl)-3-methyl-1H-pyrazole-5H-4-one. |